Universiti Malaysia Kelantan (UMK) has concluded a three-year research programme demonstrating that proteins present in the saliva of the local buffalo leech (Hirudinaria manillensis) possess significant anticoagulant capabilities comparable to medically-established treatments. The findings, disclosed by Dr Zulhisyam Abdul Kari, a senior lecturer at UMK's Faculty of Agro-Based Industry, reveal that the extracted protein contains hirudin—a naturally occurring compound that functions similarly to heparin, the standard pharmaceutical agent used to prevent unwanted blood clotting in clinical settings. Laboratory investigations confirmed the leech protein extract successfully delays coagulation at rates matching other conventional anticoagulants currently deployed in healthcare systems worldwide.
The decision to focus on buffalo leeches rather than their terrestrial counterparts stemmed from a fundamental biological advantage: these aquatic organisms produce substantially greater volumes of saliva whilst delivering markedly superior protein quality. This distinction transforms them into particularly valuable subjects for pharmaceutical development, as the yield-to-effort ratio becomes economically more favourable for potential commercialisation. The research therefore positions Malaysia's native buffalo leeches as an exceptionally promising biological resource, provided the industry infrastructure can be revitalised to support large-scale cultivation.
Leech therapy itself remains embedded within traditional and modern medical practice across multiple cultures, demonstrating historical efficacy for treating conditions ranging from gout and acne to facilitating recovery in diabetic patients suffering from chronic, slow-healing wounds. Contemporary commercial application demands rigorous adherence to clinical protocols, including the single-use principle whereby each leech treats only one patient to eliminate cross-infection risks. This safety-first approach, whilst essential, substantially increases operational costs and underscores the importance of developing pharmaceutical alternatives derived from leech saliva that can be manufactured, stored, and deployed with greater ease.
Dr Zulhisyam highlighted Asia's international reputation for producing leech specimens of exceptional quality—a standing so pronounced that affluent Western nations, notably Germany, have established supply relationships with the region. German medical institutions in particular import Asian leeches for pre-cardiac surgical applications designed to optimise blood flow before major operations. This recognition demonstrates concrete commercial demand within developed economies, with neighbouring Thailand similarly establishing import relationships to satisfy domestic medical demand. Malaysia therefore operates within an existing, proven market structure rather than attempting to pioneer an entirely novel therapeutic sector.
Yet Malaysia's leech farming industry has contracted dramatically in recent years, reversing decades of expansion that flourished under contract farming arrangements. Dr Zulhisyam attributed this decline principally to fraud incidents that systematically eroded investor confidence amongst both local and international business partners. Trust, once damaged within agricultural supply chains, recovers slowly, and the reputational harm has reportedly persisted. Simultaneously, natural leech populations inhabiting traditional habitats—particularly paddy fields integral to Malaysian agriculture—have undergone alarming depletion. The culprit lies largely in contemporary agricultural practices, specifically the indiscriminate application of pesticides and synthetic fertilisers that devastate leech populations whilst providing no countervailing benefit to farming operations unaware of or unconcerned with ecosystem impacts.
Conservation responsibility for leeches in Malaysia underwent formal institutional realignment in 2011, transitioning entirely under the Department of Fisheries Malaysia following a transfer away from the Department of Wildlife and National Parks (PERHILITAN). This restructuring reflected recognition that leeches constitute a fisheries and aquaculture resource rather than a wildlife management priority, though questions persist about whether this reclassification has enabled more effective protective measures. The regulatory framework now exists, yet resource allocation remains contested and apparently insufficient.
Dr Zulhisyam has articulated an urgent requirement for substantially increased research funding to advance molecular biology investigations capable of unlocking Malaysia's leech potential for international commercialisation. Without adequate financial support, the transition from laboratory proof-of-concept to scalable industrial production stalls indefinitely. Funding represents the critical bottleneck preventing transformation of academic discovery into economically meaningful output. The window for establishing Malaysia as a globally-recognised leech protein manufacturer may be closing, as competing nations elsewhere in Asia could develop parallel capabilities if Malaysia fails to capitalise on its current scientific momentum and indigenous species advantage.
The researcher has publicly advocated for reframing public perception of leeches, urging Malaysians to recognise them as irreplaceable biological assets rather than agricultural nuisances. This perception shift carries profound significance for policy advocacy, as it connects leech conservation to broader biotechnology aspiration and economic development rather than framing preservation as mere environmental sentiment. Every organism occupies ecological niches with cascading consequences for broader systems, yet leeches specifically offer direct commercialisable value through their unique biochemistry.
For Southeast Asian readers, this development resonates across multiple dimensions. Malaysia possesses both scientific expertise through its university research infrastructure and indigenous biological resources that competitors elsewhere might lack. The anticoagulant market remains substantial and growing, driven by ageing populations throughout developed economies and expanding middle-class demand for advanced medical interventions in emerging markets. A revitalised Malaysian leech farming sector could generate employment across rural regions, support agricultural diversification, and position the nation within high-value pharmaceutical supply chains.
However, realising these possibilities demands coordinated action spanning funding agencies, agricultural policy makers, and export regulatory authorities. The leech farming industry's previous collapse demonstrates that technical capability alone proves insufficient without institutional support and investor confidence. Fraud prevention mechanisms and transparent governance become prerequisites for attracting capital. Similarly, agricultural intensification cannot proceed indefinitely without addressing pesticide impacts on economically-valuable aquatic species.
